These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 28858531

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL.
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [Abstract] [Full Text] [Related]

  • 43. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M, oral cladribine for early MS (ORACLE MS) Study Group.
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. COVID-19 in Cladribine-treated patient with multiple sclerosis.
    Haham N, Vaknin-Dembinsky A.
    J Neuroimmunol; 2021 Oct 15; 359():577690. PubMed ID: 34390951
    [Abstract] [Full Text] [Related]

  • 53. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG, Ruck T, Aktas O, Hartung HP.
    Nervenarzt; 2018 Aug 15; 89(8):895-907. PubMed ID: 29523912
    [Abstract] [Full Text] [Related]

  • 54. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE, de Fransesco M, Mahajan K, Hengstman GJD, Schiffers KMH, Budhia S, Harty G, Krol M.
    Appl Health Econ Health Policy; 2019 Dec 15; 17(6):857-873. PubMed ID: 31444659
    [Abstract] [Full Text] [Related]

  • 55. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
    Butzkueven H, Moore N, Aydemir A, Sõnajalg J, Bezemer I, Korhonen P, Sabidó M, CLARION Study Group.
    Curr Med Res Opin; 2022 Jul 15; 38(7):1167-1176. PubMed ID: 35357268
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
    Meuth SG, Bayas A, Kallmann B, Linker R, Rieckmann P, Wattjes MP, Mäurer M, Kleinschnitz C.
    Expert Opin Pharmacother; 2022 Sep 15; 23(13):1503-1510. PubMed ID: 35930260
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.